Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 7, Issue 5, 2008, Pages 385-390

  Padman, Raj ^a   Werk, Lloyd N ^b   Ramirez Garnica, Gabriela ^b   Ye, Gang ^b   Nathanson, Ian ^b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b NEMOURS CHILDREN S HOSPITAL   (United States)

Author keywords

Body mass index percentile; Children 0 2 years old; Cystic fibrosis; Dornase alpha

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; IBUPROFEN; PANCREAS ENZYME; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; URSODEOXYCHOLIC ACID;

ACCREDITATION; AGE; ARTICLE; BACTERIAL INFECTION; BODY MASS; BODY WEIGHT; CHILD HEALTH CARE; CHILD NUTRITION; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DISEASE REGISTRY; FEMALE; GENE DELETION; HEALTH CARE FACILITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL HEALTH; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRESCRIPTION; PSEUDOMONAS AERUGINOSA; RACE DIFFERENCE; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; SWEAT TEST; TIME; TREATMENT OUTCOME;

BODY MASS INDEX; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; INFANT; MALE; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 51349127745     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2008.01.005     Document Type: Article

References (40)

1. Grosse S.D., Boyle C.A., Botkin J.R., Comeau A.M., Kharrazi M., Rosenfeld M., et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53 (2004) 1-36
2. U.S. National Screening Status Report. National Newborn Screening & Genetics Resource Center (NNSGRC). Austin, TX. Last update on 2007 March 6; Available at: URL: http://genes-r-us.uthscsa.edu/nbsdisorders.pdf. Accessed March 27, 2007
3. Borowitz D., Baker R.D., and Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 35 (2002) 246-259
4. Cystic Fibrosis Foundation. Patient registry 2004 annual report (2005), Cystic Fibrosis Foundation, Bethesda
5. Reardon M.C., Hammond K.B., Accurso F.J., Fisher C.D., McCabe E.R., Cotton E.K., et al. Nutritional deficits exist before 2 months of age in some infants with cystic fibrosis identified by screening test. J Pediatr 105 (1984) 271-274
6. Brody A.S., Klein J.S., Molina P.L., Quan J., Bean J.A., and Wilmott R.W. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 145 (2004) 32-38
7. Long F.R., Williams R.S., and Castile R.G. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 144 (2004) 154-161
8. Grosse S.D., Rosenfeld M., Devine O.J., Lai H.J., and Farrell P.M. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 149 (2006) 362-366
9. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Early airway infection, inflammation, and lung function in cystic fibrosis. [Erratum appears in Arch Dis Child. 2003 Oct;88(10):946]. Arch Dis Child 87 (2002) 306-311
10. Farrell P.M., Kosorok M.R., Rock M.J., Laxova A., Zeng L., Lai H.C., et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 107 (2001) 1-13
11. Konstan M.W., Butler S.M., Wohl M.E., Stoddard W., Matousek R., Wagener J.S., et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 142 (2003) 624-630
12. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr 147 (2005) S11-S14
13. Sims E.J., Clark A., McCormick J., Mehta G., Connett G., and Mehta A. United Kingdom Cystic Fibrosis Database Steering Committee. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics 119 (2007) 19-28
14. Waters D.L., Wilcken B., Irwing L., Van Asperen P., Mellis J., Simpson J.M., et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 80 (1999) F1-F7
15. Smyth A., and Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 3 (2003) CD001912
16. Hodson M.E., McKenzie S., Harms H.K., Koch C., Mastella G., Navarro J., et al. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 36 (2003) 427-432
17. Quan J.M., Tiddens H.A., Sy J.P., McKenzie S.G., Montgomery M.D., Robinson P.J., et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139 (2001) 813-820
18. Ramsey B.W., Astley S.J., Aitken M.L., Burke W., Colin A.A., Dorkin H.L., et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 148 (1993) 145-151
19. Nasr S.Z., Kuhns L.R., Brown R.W., Hurwitz M.E., Sanders G.M., and Strouse P.J. Use of computerized tomography and chest X-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 31 (2001) 377-382
20. Konstan M.W., Hoppel C.L., Chai B.L., and Davis P.B. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. J Pediatr 118 (1991) 956-964
21. Konstan M.W., Byard P.J., Hoppel C.L., and Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332 (1995) 848-854
22. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
23. Wolter J., Seeney S., Bell S., Bowler S., Masel P., and McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002) 212-216
24. Cystic Fibrosis Foundation. Clinical practice guidelines for cystic fibrosis (1997), Cystic Fibrosis Foundation, Bethesda
25. Konstan M.W., Butler S.M., Schidlow D.V., Morgan W.J., Julius J.R., and Johnson C.A. Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol 28 (1999) 248-254
26. Johnson C., Butler S.M., Konstan M.W., Morgan W., and Wohl M.E. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 123 (2003) 20-27
27. Sinaasappel M., Stern M., Littlewood J., Wolfe S., Steinkamp G., Heijerman H.G., et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 1 2 (2002) 51-75
28. Kerem E., Conway S., Elborn S., and Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 4 1 (2005) 7-26
29. Verbeke G., and Molenberghs G. Linear mixed models for longitudinal data (2000), Springer Verlag, New York
30. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. SAS system for mixed models (2000), SAS Institute Inc, Cary, NC
31. Berge M.T., Wiel E., Tiddens H.A., Merkus P.J., Hop W.C., and de Jongste J.C. DNase in stable cystic fibrosis infants: a pilot study. J Cyst Fibros 2 (2003) 183-188
32. Robinson T.E., Goris M.L., Zhu H.J., Chen X., Bhise P., Sheikh F., et al. Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis. Chest 128 (2005) 2327-2335
33. Grasemann H., Lax H., Treseler J.W., and Colin A.A. Dornase alpha and exhaled NO in cystic fibrosis. Pediatr Pulmonol 38 (2004) 379-385
34. Paul K., Rietschel E., Ballmann M., Griese M., Worlitzsch D., Shute J., et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 169 (2004) 719-725
35. Ratjen F., Hartog C.M., Paul K., Wermelt J., and Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 57 (2002) 930-934
36. Walker T.S., Tomlin K.L., Worthen G.S., Poch K.R., Lieber J.G., Saavedra M.T., et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 73 (2005) 3693-3701
37. Frederiksen B., Pressler T., Hansen A., Koch C., and Hoiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr 95 (2006) 1070-1074
38. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32 (2001) 277-287
39. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293 (2005) 581-588
40. Baker S.S., Borowitz D., Duffy L., Fitzpatrick L., Gyamfi J., Baker R.D., et al. Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J. Pediatr. 146 (2005) 189-193